50th Anniversary Celebration Collection

Special Section on Perspective in Drug Metabolism and Disposition, Part I—Minireview

Impact of Intracellular Lipid Binding Proteins on Endogenous and Xenobiotic Ligand Metabolism and Disposition

King Clyde B. Yabut and Nina Isoherranen

Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington

Received June 23, 2022; accepted February 10, 2023

ABSTRACT

The family of intracellular lipid binding proteins (iLBPs) is comprised of 16 members of structurally related binding proteins that have ubiquitous tissue expression in humans. iLBPs collectively bind diverse essential endogenous lipids and xenobiotics. iLBPs solubilize and traffic lipophilic ligands through the aqueous milieu of the cell. Their expression is correlated with increased rates of ligand uptake into tissues and altered ligand metabolism. The importance of iLBPs in maintaining lipid homeostasis is well established. Fatty acid binding proteins (FABPs) make up the majority of iLBPs and are expressed in major organs relevant to xenobiotic absorption, distribution, and metabolism. FABPs bind a variety of xenobiotics including nonsteroidal anti-inflammatory drugs, psychoactive cannabinoids, benzodiazepines, antiinfective, and peroxisome proliferators. FABP function is also associated with metabolic disease, making FABPs currently a target for drug development. Yet the potential contribution of FABP binding to distribution of xenobiotics into tissues and the mechanistic impact iLBPs may have on xenobiotic metabolism are largely undefined. This review examines the tissue-specific expression and functions of iLBPs, the ligand binding characteristics of iLBPs, their known endogenous and xenobiotic ligands, methods for measuring ligand binding, and mechanisms of ligand delivery from iLBPs to membranes and enzymes. Current knowledge of the importance of iLBPs in affecting disposition of xenobiotics is collectively described.

SIGNIFICANCE STATEMENT

The data reviewed here show that FABPs bind many drugs and suggest that binding of drugs to FABPs in various tissues will affect drug distribution into tissues. The extensive work and findings with endogenous ligands suggest that FABPs may also alter the metabolism and transport of drugs. This review illustrates the potential significance of this understudied area.

Introduction

Intracellular lipid binding proteins (iLBPs) are a family of ubiquitous proteins in animals that solubilize essential cellular lipids (Schaap et al., 2002; Storch and Corsico, 2008; Smathers and Petersen, 2011; Napoli, 2017). Together with avidins and lipocalins, iLBPs belong to the calycin superfamily of structurally related binding proteins. Despite low amino acid sequence homology (<10%), avidins, lipocalins and iLBPs share a common β-barrel structural fold that makes up their ligand binding cavity (Flower et al., 2000; Schaap et al., 2002; Smathers and Petersen, 2011). Avidins and lipocalins are found in both prokaryotic and eukaryotic organisms, but iLBPs are only present in vertebrate and invertebrate animals (Schaap et al., 2002). The ancestral iLBP gene evolved after animals diverged from plants and fungi, and individual isoforms arose through gene duplication and diversification (Schaap et al., 2002; Haunerland and Spener, 2004; Smathers and Petersen, 2011). The primary amino acid sequence identity for the 16 known human iLBPs ranges from 21% to 77% (Fig. 1A). Generally, the amino acid sequence identity for specific iLBPs across different species is greater than the sequence identity of all fatty acid binding proteins (FABPs) within the same species. For example, fatty acid binding protein 1 (FABP1) has >60% amino acid sequence identity across 18 different species (Zhang et al., 2020), but the sequence identity of all FABPs in humans is as low as 21%.

The human iLBPs are divided into four subfamilies (Fig. 1B) based on phylogenetic analysis and amino acid sequences (Schaap et al., 2002; Smathers and Petersen, 2011). The primary aminio acid sequence identity for specific iLBPs across different species is greater than the sequence identity of all fatty acid binding proteins (FABPs) within the same species. For example, fatty acid binding protein 1 (FABP1) has >60% amino acid sequence identity across 18 different species (Zhang et al., 2020), but the sequence identity of all FABPs in humans is as low as 21%.
Weisiger, 1993; Martin et al., 2003; Kaczocha et al., 2009; Yu et al., 2011; Zhang et al., 2020). The second and third exons are conserved in nearly all FABP genes (Zhang et al., 2020). Phylogenetic studies suggest that FABP genes evolved from a common ancestor likely through tandem duplication (Babin, 2009; Zhang et al., 2020). FABP4, 5, 8, 9, and 12 form a gene cluster on the same chromosome in humans and several other mammals. Some of these FABP genes also form clusters in aves, amphibians, and reptiles. This supports the hypothesis that vertebrate FABP genes may have arisen through continuous tandem duplication (Babin, 2009; Zhang et al., 2020).

The complete physiologic functions of iLBPs have yet to be defined, but iLBPs appear to facilitate the efficient uptake of endogenous lipids into tissues, acting as carriers to shuttle ligands through the cytosol and modulating rates of ligand metabolism (Kushlan et al., 1981; Luxon and Weisiger, 1993; Martin et al., 2003; Kaczocha et al., 2009; Yu et al., 2011; Zhang et al., 2020). The second and third exons are conserved in nearly all FABP genes (Zhang et al., 2020). Phylogenetic studies suggest that FABP genes evolved from a common ancestor likely through tandem duplication (Babin, 2009; Zhang et al., 2020).

The human iLBP genes are located in several different chromosomes (Table 1) and, like most iLBP genes in animals, have four exons with three introns (Schaap et al., 2002; Babin, 2009; Smathers and Petersen, 2011; Zhang et al., 2020). The second and third exons are conserved in nearly all FABP genes (Zhang et al., 2020). Phylogenetic studies suggest that FABP genes evolved from a common ancestor likely through tandem duplication (Babin, 2009; Zhang et al., 2020). FABP4, 5, 8, 9, and 12 form a gene cluster on the same chromosome in humans and several other mammals. Some of these FABP genes also form clusters in aves, amphibians, and reptiles. This supports the hypothesis that vertebrate FABP genes may have arisen through continuous tandem duplication from a common ancestor (Zhang et al., 2020).

The complete physiologic functions of iLBPs have yet to be defined, but iLBPs appear to facilitate the efficient uptake of endogenous lipids into tissues, acting as carriers to shuttle ligands through the cytosol and modulating rates of ligand metabolism (Kushlan et al., 1981; Luxon and Weisiger, 1993; Martin et al., 2003; Kaczocha et al., 2009; Yu et al., 2011; Zhang et al., 2020). The second and third exons are conserved in nearly all FABP genes (Zhang et al., 2020). Phylogenetic studies suggest that FABP genes evolved from a common ancestor likely through tandem duplication (Babin, 2009; Zhang et al., 2020). FABP4, 5, 8, 9, and 12 form a gene cluster on the same chromosome in humans and several other mammals. Some of these FABP genes also form clusters in aves, amphibians, and reptiles. This supports the hypothesis that vertebrate FABP genes may have arisen through continuous tandem duplication from a common ancestor (Zhang et al., 2020).
termine ligand binding, and the biochemical roles of iLBPs as they re-
on ligand binding to iLBPs, tissue expression of iLBPs, methods to de-
of xenobiotic distribution and uptake into tissues. This review focuses
high and ubiquitous expression in tissues, iLPBs may be determinants
Lee et al., 2015; Huang et al., 2018; Elmes et al., 2019). Based on their
have been associated with dyslipidemia, metabolic syndrome, obesity,
2008; Atshaves et al., 2010; Peng et al., 2012; Wang et al., 2016; Furu-
diabetes, atherosclerosis, and inflammation (Furuhashi and Hotamisi-
References: Veerkamp and Zimmerman, 2001; Noering et al., 2002; Peters et al., 2005; Schug et al., 2007; Liu et al., 2008; Storch and Corsico, 2008; Noiri et al., 2009; Rowland et al., 2009; Smathers and Petersen, 2011; Wang et al., 2014; Lee et al., 2015; Rezar et al., 2020.

2014; Gajda and Storch, 2015). Altered iLBPs function and expression
have been associated with dyslipidemia, metabolic syndrome, obesity,
disease, atherosclerosis, and inflammation (Furuhashi and Hotamisi-

<table>
<thead>
<tr>
<th>Subfamily</th>
<th>Gene</th>
<th>Molecular Weight (kDa)</th>
<th>Human Gene Locus</th>
<th>Tissue Expression Known Endogenous Ligands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subfamily I</td>
<td>RBP1</td>
<td>CRBP1</td>
<td>15.9</td>
<td>3q23</td>
</tr>
<tr>
<td>RBP2</td>
<td>CRBP2</td>
<td>15.7</td>
<td>3q23</td>
<td></td>
</tr>
<tr>
<td>RBP5</td>
<td>CRBP3</td>
<td>15.9</td>
<td>12p13.31</td>
<td>Adipose, heart, muscle</td>
</tr>
<tr>
<td>RBP7</td>
<td>CRBP4</td>
<td>15.5</td>
<td>1p36.22</td>
<td>Large intestine, heart, kidney</td>
</tr>
<tr>
<td>CRABP1</td>
<td>CRBP1</td>
<td>15.6</td>
<td>15q25.1</td>
<td>Adipose, adrenal, brain, eye, kidney, liver, large lymph nodes, muscle, pancreas, skin, small intestine, spleen, stomach, testis, thymus</td>
</tr>
<tr>
<td>CRABP2</td>
<td>CRBP2</td>
<td>15.7</td>
<td>1q23.1</td>
<td>Skin, testis</td>
</tr>
<tr>
<td>Subfamily II</td>
<td>FABP1</td>
<td>Liver FABP</td>
<td>14.2</td>
<td>2p11.2</td>
</tr>
<tr>
<td>FABP6</td>
<td>Ileal FABP</td>
<td>14.4</td>
<td>5q33.3</td>
<td>Adrenal, ovary, small intestine, stomach</td>
</tr>
<tr>
<td>Subfamily III</td>
<td>FABP3</td>
<td>Intestinal FABP</td>
<td>15.2</td>
<td>4q26</td>
</tr>
<tr>
<td>FABP2</td>
<td>Subfamily IV</td>
<td>FABP3</td>
<td>Heart FABP</td>
<td>14.9</td>
</tr>
<tr>
<td>FABP4</td>
<td>Adipose FABP</td>
<td>14.7</td>
<td>8q21.13</td>
<td>Adipose, dendirritic cells, macrophages, muscle</td>
</tr>
<tr>
<td>FABP5</td>
<td>Epidermal FABP</td>
<td>15.2</td>
<td>8q21.13</td>
<td>Adipose, brain, dendirritic cells, eye, kidney, liver, lung, macrophages, mammary gland, muscle, placenta, skin, small intestine, spleen, stomach, testis, tongue</td>
</tr>
<tr>
<td>FABP7</td>
<td>Brain FABP</td>
<td>14.9</td>
<td>6q22.31</td>
<td>Brain, central nervous, mammary gland, muscle, system glial cells, eye</td>
</tr>
<tr>
<td>FABP8</td>
<td>Myelin FABP</td>
<td>14.9</td>
<td>8q21.13</td>
<td>Peripheral nervous system myelin</td>
</tr>
<tr>
<td>FABP9</td>
<td>Testis FABP</td>
<td>15.1</td>
<td>8q21.13</td>
<td>Mammary gland, salivary gland, testis</td>
</tr>
<tr>
<td>FABP12</td>
<td>FABP12</td>
<td>15.6</td>
<td>8q21.13</td>
<td>Retina, testis</td>
</tr>
</tbody>
</table>

aMolecular weight determined by Exasy ProParam (Gasteiger et al., 2005) based on reference amino acid sequence.

bGene location obtained from the National Center of Biotechnology and Information gene database.

Crystal structures and NMR solution structures of iLBPs show that ligands are stabilized within the binding cavity by ionic interactions, hydrogen bonding networks with water molecules, and interactions with hydrophobic regions (Kleywegt et al., 1994; Cai 2011; Ragona et al., 2014). The dynamics of iLBP structures and consequen-

The tertiary structures of iLBPs are virtually superimposable and have two characteristic structural features, a β-barrel domain and helix-
turn-helix motif (Fig. 2). Ten anti-parallel β-strands fold into two β-sheets to form the β-“clam-like” cavity of the iLBPs (Fig. 2) (Furuhashi and Hotamisligil, 2008; Storch and McDermott, 2009; Ferro-
lino et al., 2013; Napoli, 2016). The two alpha-helices along with nearby loops form a portal region for ligand entry and egress into the in-
terior binding cavity (Fig. 2). The iLBPs have a characteristic finger-
print composed of three separate motifs termed FATTYACIDBP1-3 (Fig. 1A). The G-X-W triplet in the first FATTYACIDBP1 motif is highly conserved between iLBP members (Fig. 1A) and homologous with a similar motif in lipocalin family of binding proteins (Smathers and Petersen, 2011). FABP5 is unique in the iLBP family in that it is the only FABP known to form an intramolecular disulfide bond (C120-C127) (Hohoff et al., 1999). The dynamics of iLBP structures and consequen-
ces on ligand binding have been extensively studied, and several comprehensive reviews are available on this topic (Storch and McDermott, 2009; Atshaves et al., 2010; Smathers and Petersen, 2011; Ragona et al., 2014).
et al., 2012; Nossoni et al., 2014; Silvaroli et al., 2016). Hydrophobic interactions between the ligand and amino acid sidechains that line the iLBP binding cavity are important for ligand binding (Thumser et al., 1996). The residues identified as part of the hydrophobic interaction network are shown for representative iLBPs in Fig. 3A. The importance of the hydrophobic interactions is also illustrated in the general observation that binding affinities with FABPs correlate with increasing hydrophobicity (Storch and Corsico, 2008; Smathers and Petersen, 2011). Ionic and hydrogen bonding interactions for ligand binding typically involve charged residues. Phobic interactions is also illustrated in the general observation that binding cavity. Structural studies with FABP4 suggest that locking the inter-...
conformation (Gillilan et al., 2007) despite little conformational change between apo- and holo-proteins. Indeed, ligand binding kinetics with the fluorescent ligand 8-anilinonaphthalene-1-sulfonic acid (ANS) are faster in an FABP4 portal mutant (V32G, F57G, K58G), which has an enlarged portal region, than with wildtype (WT) FABP4 (Jenkins et al., 2002).

Solution NMR studies show that the backbone dynamics in the portal region in apo-proteins vary between iLBP isoforms. FABP6 has a relatively

**Fig. 3.** Binding characteristics of endogenous ligands with iLBPs. (A) The distribution of residues shown to interact with endogenous ligands for iLBPs are depicted along their structural features. Residues labeled in red font are involved in coordinating with the hydroxy or carbonyl groups of endogenous ligands via ionic interactions. (B) A top-down perspective into the aTRA binding site of hCRABP2 (PDB 1CBS) with side chains that interact with aTRA labeled. The position of R111, R132, and Y134 residues that coordinate with the carboxyl group of aTRA are shown along with the position of R59 which interacts with the β-ionone ring. (C) Side view and positions of residues R111, R132, and Y134 are shown relative to the carboxylate of aTRA along with hydrogen bonding interactions. (D) The amino acid sidechains that interact with aTRA and form the aTRA binding pocket in CRABP2 are shown. (Structures generated from PDB using ChimeraX; figure created with BioRender.com.)
rigid portal region while FABP1, 3, and 4 portal regions are more flexible, and the FABP2 portal is virtually disordered (Ragona et al., 2014). However, in general the changes in the backbone dynamics of FABPs upon ligand binding are consistent with disordered to ordered stabilizing interactions.

**Endogenous Ligand Binding in iLBPs.** The divergence of ligand specificity in iLBPs arises from nuanced differences in the β-barrel cavity and portal regions. Figure 4 shows representative structures of CRBP1, FABP1, FABP2, and FABP4 bound with their endogenous ligands illustrating general features of ligand binding with iLBPs. Historically protein fractionation, gel filtration, ion-exchange chromatography, and electrophoresis techniques were used to isolate and identify iLBPs in tissues and tissue homogenates, and bound ligands were identified from this isolated protein (Bashor et al., 1973; Ockner and Manning, 1974; Maatman et al., 1991; Veerkamp and Maatman, 1995). Subsequent characterization of ligand binding has been largely done with fluorescent probes or radiolabeled ligands in tissue homogenates or with purified recombinant iLBPs (MacDonald and Ong, 1987; Giguère et al., 1990; Nemecz et al., 1991; Sanquer and Gilchrest, 1994; Folli et al., 2000) and with x-ray crystallography and NMR (Kleywegt et al., 1994; LaLonde et al., 1994; Thompson et al., 1997; Hofhoff et al., 1999).

The known endogenous ligands of iLBPs are summarized in Table 1. The retinoid binding proteins appear to be selective toward vitamin A and its metabolites while all FABPs bind long chain fatty acids (LCFAs) (Table 1). Some FABPs also bind a variety of other endogenous ligands (Table 1). It is important to note that the list of known ligands is limited to those that have been explicitly tested for their binding and may not be comprehensive for all endogenous ligands. Several studies have explored synthetic derivatives of the endogenous ligands of FABPs (Wang et al., 2016; Floresta et al., 2017), but these synthetic derivatives are not discussed in this review. Additionally, the summary here includes binding data from species other than human proteins, as many ligand binding studies with iLBPs were done with rat, mouse, and bovine recombinant protein.

**Endogenous Ligands of Subfamily I.** Vitamin A (retinol) or its biochemically important metabolites retinaldehyde and the pharmacologically active all-trans-retinol binds the proteins in subfamily I with high affinity. Notably, all proteins in this subfamily are intracellular, in contrast to the lipocalin retinol binding protein 4 (RBP4), which is the circulating carrier for retinol. all-trans-retinol, all-trans-retinaldehyde, and their 13-cis and 9-cis isomers bind to CRBP1 (Fig. 4A) and CRBP2 with nanomolar affinity. Yet, neither all-trans-retinol nor its 13-cis and 9-cis-isomers bind to CRBPs (Kane et al., 2011; Napoli, 2016, 2017; Menozzi et al., 2017). all-trans-retinol binds to CRBP3 (Folli et al., 2001) and all-trans-retinol along with 13-cis and 9-cis retinol bind to CRBP4 (Vogel et al., 2001; Folli et al., 2002). Although CRBPs appear to be specific for retinol and retinal ligands, monoacylglycerols were also recently shown to bind to CRBPs (Lee et al., 2020). This suggests CRBPs and CRABPs may have broader ligand specificity than previously assumed. all-trans-retinol and its isomers and metabolites bind specifically to CRBP1 and CRABP2 with all-trans-retinol having higher binding affinity toward CRABP1 and CRABP2 (Kd = 0.4–39 nM) (Fiorella and Napoli, 1991; Fogh et al., 1993; Norris et al., 1994; Wang et al., 1997) than 9-cis-RA (Kd = 51–69 nM) (Norris et al., 1994) or 13-cis-RA (Kd = 156–238 nM) (Fiorella et al., 1993). Generally, all-trans-retinol appears to bind slightly tighter to CRBP1 than CRBP2 (Fiorella et al., 1993; Dong et al., 1999; Yabut and Isoherranen, 2022). Retinol or retinal isomers do not bind to CRABP1 or CRABP2 (Fiorella and Napoli, 1991; Fiorella et al., 1993; Napoli, 2017).

**Endogenous Ligands of Subfamily II.** FABP1 and FABP6 make up subfamily II. Generally, bulky ligands in addition to LCFAs bind to FABP1 and FABP6 (Smathers and Petersen, 2011). The binding pockets of FABP1 and FABP6 are larger (≥639 and 460 Å³, respectively) (Lücke et al., 2000) than other FABPs that have solvent accessible binding pockets of approximately 230 to 330 Å³ (Smathers and Petersen, 2011). FABP1 and FABP6 can accommodate larger ligands found in the liver such as bile acids, cholesterol, bilirubin, and heme (Bernlohr et al., 1997; Smathers and Petersen, 2011). Other ligands of FABP1 include branched fatty acids, endocannabinoids, acyl-CoA, prostaglandins, and vitamin K (Khan and Sorof, 1990; Thumser and Wilton, 1996; Martin et al., 2003; Storch and Corsico, 2008; Atshaves et al., 2010; Smathers and Petersen, 2011). While fatty acid ligands appear to bind to all other FABPs in a 1:1 ratio, two fatty acids can bind to FABP1 simultaneously (Fig. 4B) (Bernlohr et al., 1997; Thompson et al., 1997; Cai et al., 2012). FABP1 has a high-affinity fatty acid binding site (Kd = 4–60 nM) located deep within its interior cavity and a low affinity site (0.3–12 μM) closer in proximity to the alpha-helical domain and opening of the portal region (Fig. 4B) (Atshaves et al., 2010; Smathers and Petersen, 2011; Cai et al., 2012). With larger ligands such as bile acids, this stoichiometry appears to be reduced (1:1) along with reduced binding affinities (Kd 4–50 μM) (Richieri et al., 1995). FABP6 is structurally similar to FABP1, but due to differences in interior amino acid side chains between the two proteins, preferential ligands of FABP6 include bile acids over LCFAs (Lücke et al., 2000). Due to the size of bile acids, only a single ligand is typically observed in the FABP6 binding cavity.

**Endogenous Ligands of Subfamily III.** FABP2 is the sole member of subfamily III. In contrast to the iLBPs in subfamily II, FABP2 has a small solvent accessible binding pocket (234 Å³) (Smathers and Petersen, 2011), and its preferential ligands include saturated LCFAs.
(Fig. 4C) (Lowe et al., 1987; Richieri et al., 1994; Velkov et al., 2005; Smathers and Petersen, 2011). Measured fatty acid binding affinities with FABP2 range between 0.02 and 1.5 µM based on fluorescence displacement assays (Nemez et al., 1991; Velkov et al., 2005, 2007).

**Endogenous Ligands of Subfamily IV.** The seven members of subfamily IV collectively bind diverse lipids. The size of the solvent accessible binding pockets of subfamily IV FABPs appear to be larger than subfamily III (FABP2) but smaller than subfamily II (FABP1 and FABP6). FABP3, 4 and 8 have 323, 310, and 330 Å³ binding pockets, respectively (Smathers and Petersen, 2011). Saturated and unsaturated fatty acids bind to FABP3 with nanomolar affinity, and oxygenated fatty acids (epoxyeicosatrienoic acid, hydroxyeicosatetraenoic acid, dihydroxyeicosatrienoic acid) bind to FABP3 with Kₐ values from 0.4 to 14 µM (Widstrom et al., 2001; Smathers and Petersen, 2011). FABP4 appears to be more ligand selective, and only LCFA bind to FABP4 with nanomolar affinity (Kₐ = 22–196 nM) (Fig. 4D) (Richieri et al., 1994; Gillilan et al., 2007; Storch and Corsico, 2008; Smathers and Petersen, 2011). However, other ligands such as arfRA also bind to FABP4 but with a considerably lower binding affinity (Kₐ = 50 µM) (Matarese and Bernlohr, 1988; Veerkamp et al., 1999).

With FABP5, stearic acid and docosahexaenoic acid have nanomolar affinity to FABP5 (Kₐ = 0.17–0.29 and 0.16 µM, respectively) and oleic acid, lauric acid, and arachidonic acid binding affinity range from nanomolar to micromolar (Kₐ = 0.15–1.6, 2.5 and 0.12–1.7 µM, respectively) (Hohoff et al., 1999; Smathers and Petersen, 2011; Kaczocha et al., 2012; Pan et al., 2015; Lee et al., 2018). arfRA has also been reported to bind to FABP5 in fluorescence displacement assays with ANS (Kₐ = 35 nM) (Schug et al., 2007). However, FABP5 did not to sequester arfRA from metabolism by cytochrome P450 (CYP) enzymes, suggesting binding may not be as tight as suggested by the displacement assay (Yabut and Isoherranen, 2022). FABP7 prefers polyunsaturated fatty acids with longer chains (docosahexaenoic acid, eicosapentaenoic acid, arachidonic acid), and these fatty acids bind to FABP7 with affinities ranging from 27 to 250 nM (Smathers and Petersen, 2011).

In addition to the fatty acid ligands of FABPs, FABP3, FABP5, and FABP7 have also been shown to bind the endocannabinoids 2-arachidonoylglycerol and anandamide (AEA), and FABPs have been proposed to have a role in modulating endocannabinoid metabolism and signaling. 2-arachidonoylglycerol and AEA bind to FABP7 with higher affinity (Kₐ = 0.2 and 0.8 µM, respectively) than to FABP3 (Kₐ = 1.63 and 3.07 mM, respectively) and to FABP5 (Kₐ = 1.45 and 1.26 µM, respectively) (Kaczocha et al., 2012; Elmes et al., 2015). FABP8, 9, and 12 have not been extensively studied, and the binding of their endogenous ligands is not well characterized (Storch and Corsico, 2008; Smathers and Petersen, 2011).

**Tissue Distribution and Expression of iLBPs**

The tissue distribution of iLBPs is broad and expression patterns have been studied in several mammalian species including rat, mice, pig, and human (Paulussen et al., 1988, 1990; Gong et al., 1994; Sanquer and Gilchrest, 1994). However, species differences in tissue expression have not been comprehensively compared for all iLBPs. The following is a summary of the tissue expression of iLBPs in adult mammals determined using a combination of techniques including western and northern blot analysis, immunohistochemistry, enzyme-linked immunosorbent assay, reverse transcriptase-quantitative polymerase chain reaction, and binding assays with radiolabeled ligands. Some iLBPs are expressed in multiple tissues while others are expressed in specific tissues and cell types that may be indicative of specialized biologic functions (Storch and Corsico, 2008). The expression pattern of the FABPs is sometimes evident from the original name of the FABP, as FABPs were named after the tissues from where they were first identified. However, multiple FABPs are often expressed in the same tissues, and the expression patterns are typically broader than what is implied from the original names of the FABPs. Hence, early studies identifying FABPs in tissues often required confirming the specificity of antisera against multiple FABPs (Paulussen et al., 1990; Maatman et al., 1991; Gong et al., 1994).

Although the iLBPs are generally considered to be intracellular, FABP1, 2, 3, 4, and 5 and have also been measured in plasma in humans (0.3–13 ng/mL) (Pelsers et al., 2003; Ishimura et al., 2013). Yet their concentrations are much lower than other circulating proteins such as albumin that bind fatty acids in plasma, and the importance of the circulating FABPs is unknown. FABP4 is the only isoform shown to be secreted from tissues (adipose) into circulation (Hotamisligil and Bernlohr, 2015; Shrestha et al., 2018; Villeneuve et al., 2018). For this review only CRABPs and those FABPs that xenobiotics have been shown to bind to are discussed, but the tissue expression for all iLBPs is summarized in Table 1.

CRABP1 protein is found in various tissues including liver, kidney, stomach, lymph, eye, and brain, but it is most abundant in skin and reproductive tissues (semenal vesicles, vas deferens, and testis) (Kato et al., 1985). CRABP2 protein expression appears to be limited to skin (Giguère et al., 1990).

FABP1, or liver FABP, is the major FABP in the liver and the intestine but is also found in the kidney, lung, pancreas, and stomach (Besnard et al., 2002; Pelsers et al., 2003; Gajda and Storch, 2015; Wang et al., 2015). FABP1 is most abundant in the liver and comprises 2% to 11% of all cytosolic protein in the liver (Wang et al., 2015; Schroeder et al., 2016). Expression of FABP1 in the liver is zonal, possibly indicating a unique role in specific areas of the liver (Bass et al., 1989). Peroxisome proliferators, female sex steroids, retinoids, and a diet high in fat increase the expression of FABP1 messenger RNA (mRNA) and protein in the liver (Poirier et al., 1997; Hung et al., 2003; Trevisaskis et al., 2011; Velkov, 2013). Interestingly, FABP1 mRNA and protein expression are decreased after dexamethasone treatment, likely due to altered lipid metabolism and concentrations (Foucaud et al., 1998). In the gut, FABP1 mRNA is expressed throughout the length of the small intestines but is highest in the duodenum and jejunum (Agellon et al., 2002; Gajda and Storch, 2015). The expression pattern of FABP1 in the liver and intestines suggests FABP1 may also impact drug metabolism in the liver and drug absorption in the intestines. Additionally, FABP1 expression and function may have a role in metabolic disease progression as FABP1 polymorphisms in humans are associated with dyslipidemia, nonalcoholic fatty liver disease, and hepatocellular carcinoma (Peng et al., 2012; Schroeder et al., 2016; McKillop et al., 2019; Valizadeh et al., 2021). For example, the T94A mutation (allele frequency 26%–38%) in FABP1 alters FABP1 expression, ligand binding characteristics, protein structure and stability, and protein function (Schroeder et al., 2016). The T94A single nucleotide polymorphism is associated with elevated triglycerides, low-density lipoprotein cholesterol, and altered response to fenofibrate (Schroeder et al., 2016).

FABP2, also called intestinal FABP, is solely expressed in the gut, and its expression appears to be similar to FABP1 in rodent intestine but lower than FABP1 in human intestine. FABP2 mRNA is expressed throughout the length of the small intestine, and its expression is highest in the jejunum (Sacchettini et al., 1990; Gajda and Storch, 2015). Along with FABP1, FABP2 expression is highest in the villi of enterocytes, and it is not expressed in the crypt. FABP2 expression in enterocytes may be regulated by the gut peptide tyrosine tyrosine (Halldin and Aponte, 1997). FABP2 expression appears to be diffused throughout enterocytes but localized to the apical side in a fasted state (Alpers et al., 2000). Similar to FABP1, an A54T polymorphism in FABP2 appears to be associated...
with dyslipidemia, insulin resistance, obesity, and cardiovascular disease and may increase the risk of colorectal cancer (McKillop et al., 2019; Huang et al., 2022). FABP2 has been proposed as a potential biomarker for disruption of intestinal epithelial integrity as FABP2 is released to circulation when intestinal epithelium is compromised (Huang et al., 2022).

FABP3, or heart FABP, protein has been found in the heart, skeletal muscle, brain, kidney, liver, lung, spleen, and placenta (Paulussen et al., 1990). FABP3 is most abundant in the heart where its expression is nearly twofold greater than in skeletal muscle. Protein abundance in the kidney and brain is about half of that in the muscle and even less in the liver and placenta. FABP3 is also found to circulate at elevated levels in plasma in response to myocardial injury, presumably due to release from the heart. As such, it may be a potential biomarker for cardiovascular disease (Pelsers et al., 2005). In the kidney, FABP3 is found to be expressed in the distal and proximal convoluted tubules (Maatman et al., 1991), suggesting that tissue and is also the major FABP found in macrophages (Pelton et al., 1999; Furuhashi and Hotamisligil, 2008). FABP4 is the most abundant FABP in circulation (Ishimura et al., 2013) and is secreted from adipocytes via a membrane-bound pathway independent of the canonical endoplasmic reticulum-Golgi-plasma membrane secretion pathway (Villeneuve et al., 2018). Secreted FABP4 may serve as an adipokine, and lipolysis increases secretion of FABP4 from adipocytes (Furuhashi et al., 2015). Exogenous FABP4 influences hepatic glucose production, insulin secretion by pancreatic β-cells, and cellular functions of cardiomyocytes and smooth muscle cells (Furuhashi et al., 2015). Indeed, circulating FABP4 levels are associated with the development of insulin resistance, diabetes, atherosclerosis, cardiac dysfunction, and inflammation (Furuhashi and Hotamisligil, 2008; Ishimura et al., 2013; Furuhashi et al., 2015; Saito et al., 2021). Reduced FABP4 appears to reduce the risk of metabolic and cardiovascular disease (Hotamisligil et al., 1996; Furuhashi and Hotamisligil, 2008; Furuhashi et al., 2015), and, hence, FABP4 has been explored as a potential therapeutic target (Floresta et al., 2017). Due to its small size, FABP4 found in circulation is subject to glomerular filtration, but it accumulates in the kidney via megalin-mediated reabsorption from the tubular lumen (Shrestha et al., 2018). Notably, circulating FABP4 levels also showed a sex difference with females having higher concentrations than males (Ishimura et al., 2013).

FABP5, epidermal FABP, is the major FABP found in the epidermis, but FABP5 tissue expression is broad and not restricted to the skin (Table 1). FABP5 mRNA along with FABP3 and FABP4 mRNAs are found in human brain endothelial cells (hCMEC/D3), and FABP5 protein appears to be more abundant than FABP3 and FABP4 in these cells (Lee et al., 2015).

FABP7, brain FABP, is largely expressed in the brain and central nervous system but is also found in the skeletal muscle (Shimizu et al., 1997; Veerkamp and Zimmerman, 2001; Owada et al., 2006) with diurnal variation in its expression (Gerstner et al., 2008). FABP7 mRNA in the brain increases during light periods and declines in the dark period. This leads to an accumulation of FABP7 protein in dark periods and a decrease in protein in the light period. Yet the biologic role of this diurnal variation has not been defined.

**Xenobiotic Ligands of iLBPs and Methods to Characterize Ligand Binding**

**Known Xenobiotic Ligands of iLBPs and Their Binding Characteristics.** The literature is rich with binding and structural studies of endogenous ligands of iLBPs, but binding of xenobiotics to iLBPs has not been as extensively studied. This is despite clear evidence of xenobiotics binding to iLBPs. For example, synthetic retinoid drugs [agonists of retinoic acid receptors (RAR) and retinoid X receptors] bind to retinoid binding proteins (Ferreira et al., 2020), but the clinical relevance of the binding is not known. Whether retinoid binding proteins bind other classes of therapeutic drugs has not been explored. The majority of xenobiotic binding studies with iLBPs have been done with FABPs, likely due to their broad ligand specificity and high expression in tissues relevant to drug disposition and pharmacological activity. Of the 10 FABPs, xenobiotics have been shown to bind to FABP1–5 and FABP7 in vitro (Table 2). Xenobiotic binding to FABP6, 8, 9, and 12 has not been reported to our knowledge.

Initial binding studies of lipophilic drugs to FABP1 and FABP2 were done to explore the potential of FABP1 and 2 to facilitate drug absorption into enterocytes (Velkov et al., 2005, 2007; Chuang et al., 2008). A broad range of therapeutic drugs such as nonsteroidal anti-inflammatory drugs, peroxisome proliferator-activated receptor (PPAR) agonists (fibrates and glitazones), and benzodiazepines were shown to bind to FABP1 and FABP2 (Table 2). Additionally, due to the high expression of FABP1 in the liver, the role of FABP1 binding as the rate-limiting step in hepatocyte uptake has been explored (Rowland et al., 2015). FABP3, 4, and 5 were found to be expressed in brain endothelial cell lines, and hence, the potential of drugs to bind to these FABPs at the blood-brain-barrier was evaluated (Lee et al., 2015). Similar drugs were shown to bind to FABP3, 4, and 5 as to FABP1 and FABP2. Xenobiotic cannabinoids Δ^2^-tetrahydrocannabinol and cannabidiol also bind to FABP1 and the brain FABPs, FABP3, 5, and 7 (Elmes et al., 2015, 2019; Huang et al., 2018). Due to its role in metabolic disease, FABP4 has become a potential therapeutic target, and a variety of inhibitor ligands have been developed and their binding to FABP4 characterized (Floresta et al., 2017).

FABP1 has been a focus of binding and structural studies with PPAR agonists (fibrates, glitazones, and synthetic agonists) to probe PPAR binding specificities as they relate to interactions with residues within the binding cavity of FABP1. Ester and carboxylic acid fibrates showed distinct differences in chemical shift perturbations (CSPs) within the FABP1 binding cavity in NMR studies (Chuang et al., 2009). Carboxylic acid fibrates showed significant CSPs with residues S39, R122, S124 in FABP1 that directly interact with the carboxylate of fatty acids while ester fibrates showed far less CSPs at these residues. Additionally, thermodynamic analysis showed that binding of carboxylic acid fibrates to the high affinity site of FABP1 was mainly driven by enthalpic interactions while ester fibrates binding had a much larger entropic component (Chuang et al., 2009). These data suggest that while ionic interactions play a role in the recognition and binding specificity of non-fatty acid ligands, they are not essential for ligand binding. Hydrophobic interactions are a large component of xenobiotic binding to FABP1.

The importance of hydrophobic interactions in ligand binding is evident in structural studies with FABP4 and (S)-ibuprofen (Fig. 5A). (S)-ibuprofen binding to FABP4 is stabilized by both ionic and edge-to-face aromatic interactions with FABP4 sidechains (Fig. 5, B and C). Predicting ligand binding to FABP1 has not been reported to our knowledge. Knowledge of the structures and ligand binding characteristics of individual FABPs can aid in designing FABP isomeric specific ligands. For example, the synthetical FABP4 ligand BMS309403 binds to FABP4 (Fig. 5E) with a binding affinity of less than 2 nM but binds to FABP3 and FABP5 with >100-fold weaker affinity (Sulsky et al., 2007).
<table>
<thead>
<tr>
<th>Ligand</th>
<th>FABP1</th>
<th>FABP2</th>
<th>FABP3</th>
<th>FABP4</th>
<th>FABP5</th>
<th>FABP7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acifluorfen</td>
<td>1.1-6.0</td>
<td>4.2-8.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANS</td>
<td>11&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12&lt;sup&gt;b&lt;/sup&gt;</td>
<td>3.0-31&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.6</td>
<td>0.03-32</td>
<td>0.07-1.3</td>
</tr>
<tr>
<td>Aspirin</td>
<td>348&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3780&lt;sup&gt;b&lt;/sup&gt;</td>
<td>300-460</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atenolol</td>
<td>7.17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzafibrate</td>
<td>NB&lt;sup&gt;a&lt;/sup&gt;</td>
<td>44.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>26-100&lt;sup&gt;c&lt;/sup&gt;</td>
<td>NB</td>
<td>12</td>
<td>NB</td>
</tr>
<tr>
<td>Benзyl salicylate</td>
<td></td>
<td></td>
<td>110.8-200&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bifoxen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMS309403</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBD</td>
<td>4.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciprofibrate</td>
<td>6.9</td>
<td></td>
<td>24-72&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clofibrate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clofibrate acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortesolone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAUDA</td>
<td>0.4-1.4</td>
<td>0.3-0.7&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>22.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>41.3&lt;sup&gt;b&lt;/sup&gt;</td>
<td>110-1200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td>0.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>115&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1980-2200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diclofenac</td>
<td>3.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>35&lt;sup&gt;b&lt;/sup&gt;</td>
<td>86.3-520&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diltiazem</td>
<td>1-1.6, 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>27.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td>33</td>
<td>24</td>
<td>3.3</td>
</tr>
<tr>
<td>Fenofibrate</td>
<td>2.9</td>
<td></td>
<td></td>
<td></td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Fenoprofen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.02&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.4&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Flufenamic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(R/S) Flurbiprofen</td>
<td>1.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>222&lt;sup&gt;b&lt;/sup&gt;</td>
<td>20-70</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>1.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>179&lt;sup&gt;b&lt;/sup&gt;</td>
<td>110.5-121&lt;sup&gt;c&lt;/sup&gt;</td>
<td>NB</td>
<td>3.8</td>
<td>6.1</td>
</tr>
<tr>
<td>GW7647</td>
<td>0.3-0.6</td>
<td>1.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>25</td>
<td>7.6</td>
<td>0.7-8.9</td>
<td></td>
</tr>
<tr>
<td>(R/S) Ibuprofen</td>
<td>47.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>448&lt;sup&gt;b&lt;/sup&gt;</td>
<td>32.2-263&lt;sup&gt;c&lt;/sup&gt;</td>
<td>325</td>
<td>2.6</td>
<td>138</td>
</tr>
<tr>
<td>Indoprofen</td>
<td>1.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>161&lt;sup&gt;b&lt;/sup&gt;</td>
<td>129-520&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jasmonic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>11.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>119&lt;sup&gt;b&lt;/sup&gt;</td>
<td>9.4-2300&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketorolac</td>
<td>12.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>140&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2100-2500</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meclofenamic acid</td>
<td>0.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.3&lt;sup&gt;b&lt;/sup&gt;</td>
<td>8.9-21&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mefenamic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meproxol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>7.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nabumetone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naloxone</td>
<td>2310</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naloxone acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-naphthoxyacetic acid</td>
<td>0.06&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.8&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>56-180</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitrazepam</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perfluoromonic acid</td>
<td>1.3-3.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.4-6.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perfluoroctanoic acid</td>
<td>0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td>0.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Phenotin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pioglitazone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisolone</td>
<td>2.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>101&lt;sup&gt;b&lt;/sup&gt;</td>
<td>95-113</td>
<td></td>
<td>33</td>
<td>NB</td>
</tr>
<tr>
<td>Progesterone</td>
<td>0.03</td>
<td></td>
<td>20-32</td>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td>Propanolol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prynoline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>2.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfapyrazine</td>
<td>0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td>28.8</td>
</tr>
<tr>
<td>THC</td>
<td>0.1-2.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11-COOH-THC</td>
<td>11.2 NB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11-COOH-THC-glucuronide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11-OH-THC</td>
<td>5-7.2 NB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tolmetin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Torsemide</td>
<td>0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12.3&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trogilitazone</td>
<td>1.7</td>
<td></td>
<td></td>
<td></td>
<td>11</td>
<td>0.02-16</td>
</tr>
<tr>
<td>Valproate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Affinity for first, high affinity binding site.

<sup>b</sup>Affinity for second, low affinity binding site respectively, determined in the same study as in<sup>a</sup>.

<sup>c</sup>Includes studies where binding affinities were determined by SPR, ITC, or thermal shift with SYPRO Orange.

CBD, cannabidiol; DAUDA, 11-(dansylamino)undecanoic acid; THC, Δ<sub>9</sub>-tetrahydrocannabinol.

NB indicates that binding was tested but no binding was observed in at least one study.

References Thumser et al., 1996; Veerkamp et al., 1999; Velkov et al., 2005, 2007, 2009; Gillilan et al., 2007; Chuang et al., 2008; Rowland et al., 2009, 2015; Trevaskis et al., 2011; Kaczocha et al., 2012; Velkov, 2013; Patil et al., 2014; Yu et al., 2014; Elmes et al., 2015, 2019; Lee et al., 2015; Sheng et al., 2016; Huang et al., 2018.
Impact of Lipid Binding Proteins on Ligand Disposition 709

Methods to Measure Ligand Binding with iLBPs. Historically, measuring free ligand concentrations using separation techniques such as Lipidex-1000 (Glatz and Veerkamp, 1983; Vork et al., 1990) was used to determine ligand binding affinities to iLBPs that were isolated from tissue homogenates or recombinantly expressed and purified. However, as the concentration of free ligand is decreased via partitioning to Lipidex, these techniques generally disturb the equilibrium between ligand and iLBP, and the binding affinities are generally underestimated (apparent Kd > true Kd) using this technique (Kane and Bernlohr, 1996; Veerkamp et al., 1999). Most of the recent work to characterize xenobiotic binding to iLBPs has been done using in vitro spectrophotometric assays. The following is a brief description of the direct and indirect spectrophotometric approaches to determine xenobiotic equilibrium binding affinities along with potential caveats associated with these methods.

Direct Binding Assays. Binding affinities (Kd) of retinoids with retinoid binding proteins tightly (nanomolar affinities) are necessary to obtain accurate Kd value estimates, and hence protein fluorescence signal and instrument (fluorimeter) sensitivity can become a limitation. Therefore, retinoid binding assays are often done with protein concentrations that are much greater than the estimated Kd values. This approach may lead to inaccuracies in Kd estimates. These inaccuracies may be compounded by the use of kinetic binding models that assume steady state and that ligand binding to the binding protein does not alter free ligand concentrations in solution ([L]total ≈ [L]free). These experimental challenges likely partially explain the wide range of binding affinities reported in the literature (Norris et al., 1994; Napoli, 2016). The impact of protein concentrations and model fitting on the error in determination of the Kd values is illustrated in Fig. 6. For an iLBP-ligand interaction with a true Kd of 10 nM, using 100 nM iLBP protein (10-fold >Kd) in the experiment can result in an error as high as fivefold when a simple binding model (% iLBP bound = [iLBP bound] / [iLBP]total × 100) is fit to the data (Fig. 6B). The error becomes negligible when the quadratic binding equation (% iLBP bound = (%iLBP bound)max [P]1/2 + [L]1/2 × Kd + [P]1/2 × Kd2 − 4 × [P]1/2 × [L]1/2) is fit to the data as it accounts for ligand depletion when the iLBP concentration ranges from 0.01 to 10 times the true Kd value (Fig. 6B). However, caution should be used when using the quadratic binding equation.

Fig. 5. Binding characteristics of xenobiotic ligands of FABPs. (A) Crystal structure of hFABP4 complexed with (S)-ibuprofen (PDB 3P6H). (B) Amino acid side chains that line the binding pocket of (S)-ibuprofen in FABP4. (C) (S)-ibuprofen is stabilized in the binding pocket via ionic interactions between its carboxylate group and R126 and Y128 and edge-to-face aromatic interactions with residue F16 in FABP4. Structures for (D) hFABP1 in complex with PPARα agonist GW7647 (PDB 6DRO), (E) hFABP4 complexed with the inhibitor BMS309403 (PDB 2NNQ), (F) hFABP5 complexed with the antinociceptive SBF1-26 (PDB 5URA), and (G) hFABP3 complexed with ANS (PDB 3WBG). (Structures generated from PDB using ChimeraX; figure created with BioRender.com.)
for tight binding ligands as the dependence of $K_d$ for the model fit becomes negligible when $[P] \gg K_d$, and hence, a $K_d$ estimate may not be meaningful (Jarmoskaite et al., 2020). As such, even when the quadratic equation is used, the $K_d$ values estimated should be assumed to be the upper limit of the true $K_d$ value if the iLBP concentration in the assay exceeds the determined $K_d$ value. Nevertheless, direct fluorescence titration assays have provided extensive information on the ligand binding characteristics and binding specificities of iLBPs.

**Fluorescence Displacement Assays.** Measuring direct protein fluorescence is not always feasible due to a lack of amino acids or lack of fluorescence of the ligand. For example, FABP1 has no tryptophan residues and only one tyrosine residue, preventing the use of direct fluorescence measurements in evaluating ligand binding to FABP1. Hence, one approach for measuring direct ligand binding to FABP1 is to introduce tryptophan mutations to increase intrinsic protein fluorescence (Thumser and Wilton, 1994). However, such mutations may also affect ligand binding, and hence indirect fluorescence displacement assays are more commonly used.

Indirect measurements of ligand binding have been a common approach for estimating binding affinities for FABPs (Schug et al., 2007; Smathers and Petersen, 2011; Kaczocha et al., 2012; Elmes et al., 2015, 2019; Huang et al., 2016, 2018; Schroeder et al., 2016). Fluorescence displacement assays using fluorescent probes such as ANS or fluorescently conjugated fatty acids such as 11-(dansylamino)undecanoic acid and nitrobenzoxadiazole-stearate are commonly used due to the low intrinsic fluorescence of FABPs and the lack of measurable fluorescence from fatty acid ligands upon FABP binding. In these assays, a fluorescent probe is first bound to the FABP at a predetermined concentration, and the shift in the fluorescence of the ligand upon protein binding is measured. The drug of interest is then titrated into the sample, and the decrease in the probe fluorescence due to probe displacement by the drug is measured. Because displacement of the probe is assumed to be a purely competitive interaction, inhibitory constants ($K_i$) are determined either from a direct fit of a competitive binding model to the fluorescence data or are calculated from $EC_{50}$ values assuming competitive inhibition (Velkov et al., 2005; Chuang et al., 2008; Lee et al., 2015; Elmes et al., 2019). Interfering fluorescence at similar wavelengths as the probe from the ligand of interest should be considered in these assays as this may confound the binding data. For example, arRA has a similar fluorescence emission peak (475 nm) as the fluorescent probe ANS (480 nm) with excitation wavelengths at 350 and 380 nm, respectively (Fiorella et al., 1993; Huang et al., 2014; Vogler, 2015). This fluorescence overlap may affect the interpretation of ANS displacement data for arRA binding to FABPs.

For most FABPs the assumption of competitive binding is likely inappropriate as only one ligand appears to bind at a time to FABPs (Figs. 4 and 5). However, with FABP1, which can have multiple ligands bound to it simultaneously (Fig. 4b), a simple competitive binding model may not be appropriate, and $EC_{50}$ or $IC_{50}$ values determined with ligand displacement assays with FABP1 should not be directly translated to $K_d$ or $K_i$ values. It is possible that a ligand can bind simultaneously with a fluorescence probe to the FABP or that the binding of one fluorescent probe molecule affects the binding affinity of the ligand tested that may bind to a second binding site.

Similar concerns may be relevant for FABP2, although endogenous ligands appear to bind to FABP2 with 1:1 stoichiometry, possibly due to the size of the ligands. In FABP2, ANS and ketorolac have been shown to bind to different binding sites based on fluorescence and isothermal titration calorimetry data (Patil et al., 2014). This suggests that the two ligands could also bind simultaneously. However, there is currently no
structural evidence that two ligands bind to FABP2 simultaneously. In the case of FABP1 and FABP2, it is unclear whether it is possible for a ligand to bind to the second binding site without affecting the binding of the fluorescent ligand in the first, high affinity binding site. The probe fluorescence intensity or the wavelength maxima of the probe fluorescence may be allosterically affected by binding of a ligand at an additional binding site, or complete displacement of the fluorescent probe may only occur when all binding sites are occupied by the xenobiotic ligand. Hence, alternative kinetic binding models may be more appropriate than a purely competitive one.

Like the direct binding assays described here, limitations with fluorescence signal, instrument sensitivity, and protein and probe concentrations should be carefully considered with displacement assays. Figure 6C shows simulated fluorescence displacement assay where the true affinity for the probe \( K_d \) and test ligand \( K_d \) are the same (10 nM). Using an iLBPs concentration of 100 nM (10-fold greater than the \( K_d \)) can result in a >10-fold error in the estimated \( K_i \) value, illustrating the potential confounding effects of experimental design on the data collected (Fig. 6, C and D).

**Impact of iLBPs on Ligand Distribution and Metabolism**

One of the biologic functions of iLBPs is to serve as lipid carriers that bind, solubilize, and shuttle their ligands to relevant cellular compartments (Storch and Corsico, 2008; Storch and Thumser, 2010). iLBPs may simply bind their often unstable or toxic ligands to stabilize the ligand or prevent ligand interactions with nonspecific proteins in a cell. However, iLBPs have been shown to interact with phospholipid membranes, associate with cellular compartments such as mitochondria and lysosomes, and interact with different metabolic enzymes and nuclear receptors, suggesting more broad functions in a cell. Three different mechanisms for the impact of iLBPs on ligand disposition have been proposed (Fig. 7) (Smith and Storch, 1999; Storch and Corsico, 2008). In the first model, the iLBPs release their ligands to solution (diffusional model). Alternatively, iLBPs may interact with the phospholipid membranes via direct protein-membrane interactions to accept their ligands from or release their ligands directly to the membrane (collisional model). Finally, iLBPs may participate in direct protein-protein interactions and channel their ligands directly to catalytic enzymes or transporters. Since FABPs are highly expressed in tissues relevant to xenobiotic disposition, it is likely that xenobiotics bind to FABPs in these tissues, and the three models of iLBP functions may also be relevant for xenobiotic disposition. The following sections summarize various studies on the impact of iLBPs on ligand distribution and metabolism and the possible mechanisms of ligand delivery.

**Impact of FABPs on Ligand Uptake into Tissues.** The role FABPs have in regulating the uptake and tissue distribution of their endogenous ligands has been studied for many FABPs to which xenobiotic ligands also bind. It is well established that FABP1 facilitates lipid uptake into the liver, and FABP1 expression in the liver correlates with uptake of fatty acids (Kushlan et al., 1981; Hung et al., 2003; Newberry et al., 2003). Induction of FABP1 expression by PPAR agonists in HepG2 cells resulted in increased rates of oleate uptake, while knocking down FABP1 expression significantly reduced rates of uptake (Wolfrum et al., 1999). Changes in uptake appear to also alter lipid metabolic products. FABP1-knockout mice have decreased rates of \([H]_3\text{oleate}\) uptake to the liver, which corresponds to decreased fatty acid \( \beta \)-oxidation and incorporation of \([H]_3\text{oleate}\) into triglycerides (Newberry et al., 2003). In rat perfused livers, higher expression of FABP1 in the liver correlated with greater palmitate clearance and higher retention of palmitate and its metabolites in the liver (Hung et al., 2003). Similarly, FABP5 and FABP7 that are expressed in the brain appear to enhance endocannabinoid uptake into cells and endocannabinoid metabolism. The cellular uptake of AEA and subsequent metabolism by fatty acid amide hydrolase was greater in N18TG2 (mouse neuroblastoma) and COS-7 cells transfected with FABP5 and FABP7 when compared to mock transfected cells while FABP3 had no effect (Kaczocha et al., 2009).

FABP2 appears to play a role in the cellular uptake and distribution of xenobiotic ligands in the gut, and many orally administered drugs bind to FABP2 (Table 2). The potential role of FABP2 in modulating apical and basolateral transport of drugs in the intestine was studied in the parallel artificial membrane permeability assays where an artificial phospholipid membrane separates donor and acceptor reservoirs (Velkov et al., 2007). These studies were designed to test the effect of FABP2 on the rates of diffusion across an artificial phospholipid membrane mimicking the apical membrane of enterocytes. For apical membrane permeability, drugs were added to the donor side, and physiological concentrations of FABP2 in the enterocytes (0.33 mM) were present on the acceptor side. The rates of drug uptake from the apical membrane were increased for drugs that bound to FABP2, with tighter binding drugs showing higher rates of uptake. This suggests that FABP2 may facilitate drug absorption in the small intestine. In support of these findings, FABP2 appears to also increase rates of drug uptake in perfused rat intestines. In rats, FABP1 and FABP2 mRNA expression in the gut increased.
Fig. 8. Simulation of the impact of varying ligand to iLBP ratios on metabolic enzyme activity under the circumstances that the iLBP interacts directly with the metabolic enzyme. (A) An enzyme kinetic scheme showing the overall model used for the simulations where apo-iLBP directly inhibits the enzyme and holo-iLBP can deliver substrate to the enzyme via protein-protein interactions. (B) Simulated concentrations of the metabolite (product) formation, enzyme-substrate complex concentrations, concentrations of the ternary iLBP-substrate-enzyme complex, iLBP-enzyme complex, free substrate in solution, and iLBP-substrate complex as a function of time when the ratio of the substrate concentration to binding protein concentration is varied, and all the processes are simulated according to the scheme in A. The substrate concentrations were 1 nM (red line), 10 nM (blue, orange, and purple lines) and 20 nM (green line). The iLBP concentration was either 1 nM (blue), 10 nM (green, orange, and red lines), or 20 nM (purple line). The kinetic and catalytic rate constants used in the simulations are listed in a table in (A). The enzyme concentration in all simulations was 0.5 nM. (Figure created with BioRender.com.) MATLAB code used for simulations is provided in Supplementary Material.
approximately 1.5- to twofold by feeding a high-fat diet. Compared with control-fed rats, this higher expression of FABP1 and FABP2 correlated with nearly twofold higher rates of disappearance of ibuprofen (disappearance $P_{\text{app}}$ 158 versus 97 × 10$^6$ cm/s) and midazolam (disappearance $P_{\text{app}}$ 239 versus 143 × 10$^6$ cm/s) from intestinal perfusate and increased accumulation of the drugs in the intestinal tissue (Trevaskis et al., 2011). This suggests that FABPs may facilitate the uptake of these drugs into the enterocytes (Trevaskis et al., 2011). Interestingly, significantly less 4-hydroxy-midazolam was quantified in mesenteric blood in animals with elevated FABP, and the extraction ratio of midazolam by the intestine was decreased from 11% to 7% in rats with higher FABP1 expression compared with control-fed rats. This suggests that midazolam likely bound to FABP1 in the enterocytes, altering midazolam metabolism in the enterocytes (Trevaskis et al., 2011). Despite these findings, the contribution of FABPs to rate and extent of drug absorption has received relatively little attention.

The potential impact of FABP binding on drug distribution is clear from the high expression of FABPs in different tissues and the capacity of FABPs for drug binding in a variety of tissues throughout the body. Binding of numerous drugs that target the central nervous system to FABP3, FABP4, and FABP5, which are expressed in the brain, was proposed to impact the distribution of drugs across the blood-brain barrier (Lee et al., 2015). This process is similar to the regulation of endogenous docosahexaenoic acid concentrations in the brain by FABP5 (Pan et al., 2015, 2016). Current models (Ussey et al., 2020) for predicting tissue distribution of drugs and tissue partition coefficients ($K_p$ values) do not account for specific protein binding sinks in tissues, and hence extensive FABP binding in any tissue is not considered when distribution kinetics are modeled. As physiologically based pharmacokinetic models of drug distribution become more mainstream, incorporation of FABP binding into tissue distribution models and considering FABP binding when rates of distribution are considered will become increasingly important.

**Ligand Delivery to Membranes.** It remains unclear whether the observed changes in lipid metabolism that correlate with FABP expression are simply because FABPs provide an intracellular reservoir to increase uptake of their ligands to cells and, hence, the availability of ligands to sites of metabolism (diffusional model, Fig. 7A) or if FABPs deliver ligands via specific interactions to enzymes or to cellular membranes. The mechanism of ligand transfer from FABPs to model phospholipid membranes has been studied for FABPs 1–5 using fluorescent fatty acids as ligands (Storch and Thumser, 2000). The rates of ligand transfer from FABPs to phospholipid membranes could be measured via quenching of fluorescence upon fatty acid ligand incorporation into the phospholipid membrane. The rate of ligand transfer from FABP1 to acceptor membranes was not affected by the concentrations or composition of phospholipid. However, FABP1 transfer rates were substantially impacted by the ionic strength of the surrounding aqueous medium. These data suggest that FABP1 does not interact directly with phospholipid membranes and that ligand delivery to model membranes requires release of ligand into solution (Hsu and Storch, 1996).

In contrast, the transfer rates of FABPs 2–5 were proportional to phospholipid concentration in acceptor membranes and affected by membrane phospholipid composition (Kim and Storch, 1992; Wootan et al., 1993; Hsu and Storch, 1996; Storch and Thumser, 2000). FABP2 was shown to also accept fatty acids from donor membranes. Faster fatty acid transfer rates from donor membranes to FABP2 were observed with negatively charged membranes compared with zwitterionic membranes (Thumser and Storch, 2000). Taken together, these data suggest that FABPs 2–5 directly deliver their ligands to phospholipid membranes via ionic interactions. The structural basis for this interaction has been elucidated with mutagenesis studies with FABP2. These studies suggest that the alpha-helical domain in FABP2 is important for these interactions (Corsico et al., 1998; Falomir-Lockhart et al., 2006). The rate of fatty acid transfer from a helix-less FABP2 variant to phospholipid membrane models was unaffected by increasing phospholipid concentration compared with WT, suggesting the loss of the helices also eliminates the membrane interactions (Corsico et al., 1998). Additionally, WT FABP2 could outcompete cytochrome c interactions with anionic membranes, but this function was severely disrupted with the helix-less variant. These findings were corroborated with later mutational studies showing that charged lysine residues in the alpha-helical region are critical for efficient fatty acid transfer (Falomir-Lockhart et al., 2006). The significance of this protein-membrane interaction in vivo is unknown but may play a role in the uptake and targeting of ligands to specific cellular organelles (Hsu and Storch, 1996).

**Ligand Delivery by iLBPs to Enzymes and Receptors.** The role of iLBPs in delivering their ligands to metabolic enzymes or receptors via protein-protein interactions and substrate channeling has been most extensively studied with the retinoid binding proteins (Napoli, 2017). Possibly due to the reactivity and potential toxicity of retinoids, the retinoid binding proteins appear to modulate and direct retinoid metabolism and signaling via a network of protein-protein interactions. Extensive kinetic and metabolic studies have been conducted (Napoli, 2016, 2017) in rat and human intestinal and liver microsomes with holo-CRBP. In these studies, despite the tight binding of the ligands with the CRBPs, the apparent $K_a$ values for the total ligand are often significantly decreased or unaltered when the ligand is entirely bound to the CRBP in comparison with free ligand (Ong et al., 1987; Herr et al., 1999, Napoli, 2016, 2017). This kinetic data cannot be explained by the diffusional model (free drug hypothesis) and have been interpreted through protein-protein interactions between the CRBPs and retinoid metabolizing enzymes. Consistent with the protein-protein interaction model, apo-CRBP1 appears to also inhibit retinol esterification by lecithin retinol acyltransferase enzyme suggesting a function of the apo-CRBP1 in regulating metabolism even in the absence of its ligand. These data suggest that the ratio of apo- to holo-CRBP1 or the ratio of CRBP1 to its ligand may have an important role in regulating vitamin A homeostasis in the cell. This concept is illustrated via kinetic simulations in Fig. 8. Yet these observations are limited to endogenous retinoids and their specific metabolic enzymes, and the importance to drug metabolism by major drug-metabolizing enzymes is unknown.

Protein-protein interactions between CRABPs and nuclear RARs have also been extensively studied (Dong et al., 1999; Budhu et al., 2001; Schug et al., 2007; Majumdar et al., 2011). Expression of CRABP2 but not CRABP1 in Cos7 cells enhances RAR transactivation (Dong et al., 1999), and the transfer rate of allRA from CRABP2 to RAR appears to be dependent on RAR acceptor concentration while transfer rates from CRABP1 are unaffected by changes in RAR concentration. Holo-CRABP2 also appears to translocate to the nucleus via a SUMOylation dependent mechanism to channel allRA directly to RAR (Majumdar et al., 2011). These findings demonstrate the potential role that iLBPs may have in cellular targeting of their ligands and delivery of their ligands to target receptors, and suggest that iLBP interaction may be protein specific.

The impact of the CRABPs on allRA hydroxylation has also been studied in rodent microsomes (Napoli et al., 1991; Fiorella and Napoli, 1994), with recombinant drug metabolizing CYPs, CYP3A4, and CYP2C8 and with the allRA hydroxylases CYP26A1, CYP26B1, and CYP26C1 (Nelson et al., 2016; Zhong et al., 2018; Yabut and Isoherranen, 2022). Recently holo-CRABP2 was also shown to be a substrate of CYP2C1, a retinoid desaturase in the skin (Glass and Guengerich, 2021). As expected from the tight binding of allRA to CRABP1 and
CRABP2, CYP3A4 and CYP2C8 mediated metabolism of arA was nearly completely abolished when arA was bound to the CRABPs, consistent with the free drug hypothesis (Nelson et al., 2016; Yabut and Isoherranen, 2022). However, with the CYP26 enzymes, efficient arA formation was observed also when arA was completely bound to CRABPs. The apparent Ka values for holo-CRABPs were either unchanged or decreased when compared with free ligand in solution. Surprisingly the kcat values for arA hydroxylation were also significantly decreased in the presence of CRABPs for all three CYP26 enzymes. This suggests that apo-CRABPs inhibit CYP26 enzymes via a noncompetitive mechanism similar to the inhibition observed between CRBPs and lecithin retinol acyltransferase. The observed kinetics could be explained using a substrate channeling model incorporating direct protein-protein interactions between CYP26 and apo- and holo-CRABPs (Nelson et al., 2016; Yabut and Isoherranen, 2022).

The binding protein (CRBP, CRABP)-enzyme interactions may be critical modulators of ligand metabolism and vitamin A homeostasis in cells in a ligand concentration dependent manner, and the phenomenon may be important for other iLBPs as well. This hypothesis was explored via kinetic simulations of the effect of the binding protein-ligand ratio on the metabolic rates and ligand clearance in a cell (Fig. 8). The simulations show how altered expression of the binding proteins will change ligand metabolism and concentrations through direct protein-protein interactions between the apo- and holo-binding protein and the metabolic enzyme. When substrate is in excess to the binding protein, the substrate is relatively freely metabolized (Fig. 8, blue and green lines) allowing for homeostasis to be maintained. However, under circumstances of substrate deficiency when the binding protein is in excess to substrate, nearly all of the enzyme is bound by the apo-binding protein, severely inhibiting metabolism (Fig. 8, red and purple lines).

In addition to the retinoid binding proteins, the FABPs have also been shown to directly interact with nuclear receptors and metabolic enzymes. Similar to holo-CRABP2 channeling arA to RARs, FABP1, FABP4, and FABP5 have been shown to translocate to the nucleus upon ligand binding to enhance PPAR transactivation (Wolfrum et al., 2001; Tan et al., 2002; Schug et al., 2007; Hostetler et al., 2009; Velkov, 2013). Physical interactions between FABPs and PPARs have been demonstrated using biochemical and biophysical assays (communoprecipitation, circular dichroism, fluorescence resonance energy transfer, and NMR). These studies suggest that FABP-PPAR interactions are protein specific. FABP1, FABP4, and FABP5 specifically activate and interact with PPAR, PPAR, and PPAR, respectively, and the extent of transactivation appears to be ligand dependent.

FABP4 and FABP5 have been shown to directly interact with hormone sensitive lipase (HSL) (Jenkins-Kruchten et al., 2003; Storch and Corsico, 2008; Storch and Thumser, 2010) to promote the liberation of free fatty acids from triglycerides in times of fatty acid scarcity. FABP4 and FABP5 showed ligand dependent interactions with HSL in isotermal titration calorimetry experiments and increased HSL catalytic activity by approximately twofold (Jenkins-Kruchten et al., 2003). Similarly, FABP1 has been shown to interact with carnitine palmitoyltransferase I (CPTI), a key mitochondrial enzyme for fatty acid β-oxidation (Hostetler et al., 2011). Significant deviation from the theoretical circular dichroism (CD) spectra of the C-terminal and active domain of CPTI was observed in the presence of FABP1. The affinity (Kd) between FABP1 and CPTI was 2.5 nM as determined by fluorescence resonance energy transfer binding assays. Notably, FABP1 enhanced CPTI activity to metabolize LCFA-CoA to LCFA-carnitine demonstrating facilitation of the rate-limiting step in fatty acid β-oxidation. Given the broad binding specificity of FABP1 and FABP2 for various xenobiotics and their high abundance in the liver and intestine, it is likely that FABPs also impact drug metabolism via similar mechanisms in vivo.

This hypothesis is supported by the finding that FABP1 binds Δ9-tetrahydrocannabinol and the rate of Δ9-tetrahydrocannabinol metabolism is altered in FABP1-knockout mice (Elmes et al., 2015).

While FABP interactions with transporters have not been extensively studied, several groups have reported that FABP4 directly interacts with the fatty acid uptake transporter CD36 to mediate fatty acid metabolism (Spitsberg et al., 1995; Glatz and Luiken, 2018; G Yamaf i et al., 2021). CD36 appears to act as an intracellular docking site for FABP4 to facilitate fatty acid transfer to the cytoplasm where FABP4 may then shuttle fatty acids to the peroxisomes or mitochondria for fatty acid metabolism.

Conclusions
iLBPs are ubiquitously expressed small binding proteins in tissues, which bind a variety of lipophilic compounds and facilitate the cellular uptake, diffusion, and subsequent metabolism of their endogenous ligands. Yet despite the plethora of work that exists to define biochemical functions of iLBPs, their impact on xenobiotic disposition is poorly defined, and very few studies have explored the binding characteristics of various drugs with FABPs. Many xenobiotics also bind to FABPs that are highly expressed in major organs that govern drug absorption and clearance with micromolar to submicromolar affinity in vitro. Based on the high expression of FABPs (up to 11% of all cytosolic protein), it is likely that FABPs also bind xenobiotics in vivo.

The importance of FABP binding in drug disposition is not understood; however, limited studies have shown that absorption and clearance of drugs that bind to FABPs is linked to FABP expression in animal models. These findings suggest that FABPs have the potential to be determinants of xenobiotic disposition. Variability in FABP binding/ expression may explain some intra- and interindividual variability in drug disposition as FABP expression changes with diet, disease states, and administration of other therapeutics. Whether FABPs directly affect xenobiotic access to drug-metabolizing enzymes remains a knowledge gap. It is unclear if FABPs may simply provide an intracellular “sink” to increase the partitioning and availability of free drug accessible for metabolism within cells or if FABPs directly interact with metabolic enzymes to alter rates of drug metabolism. Further studies are needed to elucidate these mechanisms, which would provide insight into how FABPs may regulate xenobiotic disposition.

Data Availability
The authors declare that all the data supporting the findings of this study are available within the paper and its Supplemental Material.

Authorship Contributions
Participated in research design: Yabut, Isoherranen.
Participated in data collection: Yabut.
Performed data analysis: Yabut, Isoherranen.
Wrote or contributed to the writing of the manuscript: Yabut, Isoherranen.

References
Title: Impact of Intracellular Lipid Binding Proteins on Endogenous and Xenobiotic Ligand Metabolism and Disposition

Authors: King C. B. Yabut, Nina Isoherranen

Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, 98195

Drug Metabolism and Disposition, 2023

%This script was used for binding simulations in Figure 6A and 6C.
%The for loop outputs the concentration of species bound and unbound at
%equilibrium for every nM concentration of i (e.g. Probe = i will simulate
%binding for every concentration of Probe from 1-1000nM given the
%concentration of iLBP, Drug, etc.). For direct titration simulations,
k3 and k4 were set to 0. For fluorescence displacement simulations,
k3 and k4 are defined as the on and off rates (k4/k3 = Kd) of the drug
%that displaces Probe from iLBP.
%iLBP-Probe_compiled variable outputs the concentration of iLBP bound with
%Probe for every concentration of i at the end of the simulation and at
%binding equilibrium. This was used to determine the % of iLBP bound in the
%simulations shown in Figure 6A and 6C.

clear all; clc

iLBP_Probe_compiled = zeros(1,1000);

for i = 1:1000

%define length of simulation in minutes (ex. from 0-5min spaced by 0.001min
%==> timespan = [0:0.001:10]
timespan = [0:0.1:5];

%define kinetic parameters in model:
k1 = 1; %kon Probe-iLBP (nM^-1 min^-1)
k2 = 10; %koff Probe-iLBP (min^-1)
k3 = 0; %kon Drug-iLBP (nM^-1 min^-1)
k4 = 0; %koff Drug-iLBP (min^-1)

%define initial (t=0) concentrations of each species in nM:
Probe = i;
iLBP = 10;
iLBP_Probe = 0;
Drug = 0;
iLBP_Drug = 0;

yinitial = [Probe, iLBP, iLBP_Probe, Drug, iLBP_Drug]; %defines a row
%vector containing initial concentrations for ode15s call

%call for ode15s solver, solves the system of ODE in 'binding' function
[t, y] = ode15s(@(t,y) binding(t, y, k1, k2, k3, k4), timespan, yinitial);

%the following outputs the concentrations of all species after the
%simulation time
[Probe_end] = y(end, 1);
[iLBP_end] = y(end, 2);
[iLBP_Probe_end] = y(end, 3);
[Drug_end] = y(end, 4);
[iLBP_Drug_end] = y(end, 5);

%the following outputs the ODE solutions for each individual species
Probe = y(:,1);
iLBP = y(:,2);
iLBP_Probe = y(:,3);
Drug = y(:,4);
iLBP_Drug = y(:,5);

iLBP_Probe_compiled(i) = iLBP_Probe_end;
end

iLBP_Probe_compiled = iLBP_Probe_compiled';

%these plot individual species separately but only for the very last
%concentration defined by i, remove % in front of each line to plot
%plot(t, Probe, 'linewidth', 1, 'color', 'k');
%hold on
%plot(t, iLBP, 'linewidth', 1)
%hold on
%plot(t, iLBP_Probe, 'linewidth', 1)
%hold on
%plot(t, Drug, 'linewidth', 1)
%hold on
%plot(t, iLBP_Drug, 'linewidth', 1)

%legend ('Probe', 'iLBP', 'iLBP-Probe', 'Drug', 'iLBP-Drug')
%title()
%xlabel('Time (min)')
%ylabel('Concentration (nM)')

function  dydt = binding(t, y, k1, k2, k3, k4);

dydt = zeros(5, 1);
dydt(1) = k2*y(3) - k1*y(1)*y(2); %Probe differential equation
dydt(2) = k2*y(3) + k4*y(5) - k1*y(2)*y(1) - k3*y(2)*y(4); %iLBP differential equation
dydt(3) = k1*y(2)*y(1) - k2*y(3); %iLBP-Probe differential equation
dydt(4) = k4*y(5) - k3*y(2)*y(4); %Drug differential equation
dydt(5) = k3*y(2)*y(4) - k4*y(5); %iLBP-Drug differential equation

%y(1) = Probe
%y(2) = iLBP
%y(3) = iLBP-Probe
%y(4) = Drug
%y(5) = iLBP-Drug

end
%This script reproduces kinetic simulations in Figure 8B with 10 nM substrate and 20 nM iLBP (purple lines)
clear all; clc

timespan = [0:0.1:10];

%define kinetic parameters in model:
k1 = 1; %kon S-E (nM^-1 min^-1)
k2 = 4.7; %koff S-E (min^-1)
k3 = 1.07; %kon S-iLBP (nM^-1 min^-1)
k4 = 4.4; %koff S-iLBP (min^-1)
k5 = 1; %kon iLBP-E (nM^-1 min^-1)
k6 = 0.39; %koff iLBP-E (nM^-1 min^-1)
k7 = 1; %kon iLBP-S-E
k8 = 0.99; %koff iLBP-S-E
kcat = 1.1; %(min^-1)
betakcat = 0.83; %(min^-1)

%define initial (t=0) concentrations of each species in nM:
S = 10;
E = 0.5;
ES = 0;
P = 0;
iLBP = 20;
iLBPS = 0;
iLBPE = 0;
iLBPSE = 0;
yinitial = [S, E, ES, P, iLBP, iLBPS, iLBPE, iLBPSE]; %defines a row vector containing initial concentrations for ode15s call

initial_iLBP_S_ratio = iLBP./S; %outputs the initial ratio of iLBP to S

%call for ode15s solver, solves the system of ODE in 'channeling' function
[t, y] = ode15s(@(t,y) channeling(t, y, k1, k2, k3, k4, k5, k6, k7, k8, kcat, betakcat), timespan, yinitial);

%the following outputs the concentrations of all species after the incubation time
[Send] = y(end, 1);
[Eend] = y(end, 2);
[ESend] = y(end, 3);
% the following outputs the ODE solutions for each individual species
S = y(:,1);
E = y(:,2);
ES = y(:,3);
P = y(:,4);
iLBP = y(:,5);
iLBPS = y(:,6);
iLBPE = y(:,7);
iLBPSE = y(:,8);
compiled = [P ES iLBPSE iLBPE S iLBPS];

final_apo_holo_ratio = iLBPend./iLBPSend; %final ratio of apo to holo after incubation time

% these plot individual species separately, exclude by add % in front
plot(t, S, 'linewidth' , 1, 'color' , 'k');
hold on
plot(t, E, 'linewidth' , 1)
hold on
plot(t, ES, 'linewidth' , 1)
hold on
plot(t, P, 'linewidth' , 1)
hold on
plot(t, iLBP, 'linewidth' , 1)
hold on
plot(t, iLBPS, 'linewidth' , 1)
hold on
plot(t, iLBPE, 'linewidth' , 1)
hold on
plot(t, iLBPSE, 'linewidth' , 1)
ylim([0 1]);
legend ( 'S' , 'E' , 'E-S' , 'P' , 'iLBP' , 'iLBP-S' , 'iLBP-E' , 'iLBP-S-E' )
title( '10 nM S, 20 nM iLBP' )
xlabel( 'Time (min)' )
ylabel( 'Concentration (nM)' )

function dydt = channeling(t, y, k1, k2, k3, k4, k5, k6, k7, k8, kcat, betakcat);

dydt = zeros(8, 1);
dydt(1) = k2*y(3) + k4*y(6) - k1*y(1)*y(2) - k3*y(1)*y(5); % S differential equation
dydt(2) = k2*y(3) + k6*y(7) + k8*y(8) + kcat*y(3) - k1*y(1)*y(2) - k5*y(2)*y(5) - k7*y(2)*y(6); % E differential equation
dydt(3) = k1*y(1)*y(2) - k2*y(3) - k4*y(6) - kcat*y(3); % E-S differential equation
dydt(4) = kcat*y(3) + betakcat*y(8);

% P differential equation

dydt(5) = k4*y(6) + k6*y(7) - k3*y(1)*y(5) - k5*y(2)*y(5);

%iLB differential equation

dydt(6) = k3*y(1)*y(5) + k8*y(8) - k4*y(6) - k7*y(2)*y(6);

%iLB-S differential equation

dydt(7) = k5*y(2)*y(5) + betakcat*y(8) - k6*y(7);

%iLB-E differential equation

dydt(8) = k7*y(2)*y(6) - k8*y(8) - betakcat*y(8);

%iLB-S-E differential equation

% y(1) = S
% y(2) = E
% y(3) = E-S
% y(4) = P
% y(5) = iLB
% y(6) = iLB-S
% y(7) = iLB-E
% y(8) = iLB-S-E

%end

Published with MATLAB® R2021b